Insulet Corporation · NASDAQ:PODD
Insulet — Investor Presentation (September 2023)
19 slides from Insulet's investor presentation, September 2023
Slide 1: Market Opportunity & Impact of GLP-1s
Insulet Corporation Market Opportunity & Impact of GLP-1s September 2023 Christian D Podder since 2020 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 3: Introduction
Introduction • Ongoing adoption of the GLP-1 class of drugs in diabetes and recent news surrounding the expansion of use of GLP-1 in obesity have led to several questions regarding the impact on the insulin therapy market • This report is intended to provide investors and other interested parties wi
Slide 4: Overview
Overview • There are two distinct types of diabetes, type 1 and type 2. Both are comprised of large patient populations, and represent significantly underpenetrated markets for insulin pump therapy (p. 5). • Type 1 diabetes is an autoimmune disease that presents acutely and always requires insulin f
Slide 5: Massive Market Opportunity
Massive Market Opportunity 537M 1.3B The Obvious Choice 2022 2050 People with Diabetes Worldwide1, 2 Omnipod Platform • No needles or tubes ~64M • Discreet, wearable, disposable • Pay-as-you-go economics for customers and Requiring Insulin Worldwide1 payors in the U.S. and certain int’l markets • Ea
Slide 6: Type 1 Diabetes
Type 1 Diabetes Insulet
Slide 7: Type 1 diabetes is an autoimmune condition with rapid onset, permanent loss of beta cells, and no cure
Type 1 diabetes is an autoimmune condition with rapid onset, permanent loss of beta cells, and no cure The body attacks beta cells resulting in cell What causes type 1 diabetes? death and the need for exogenous insulin • Type 1 diabetes is an immune-mediated disease associated with destruction of th
Slide 8: Underpenetrated Type 1 Diabetes Market
Underpenetrated Type 1 Diabetes Market U.S. Type 1 Diabetes International Type 1 Diabetes Population Population1 2022 2022 ~1.5M ~3.5M ~60% ~80% ~40% ~20% T1 US T1 US Insulin Pumps Insulin Pumps Multiple Daily Injections Multiple Daily Injections Note: Insulet internal estimates 1. In the markets we
Slide 9: Type 1 Diabetes and GLP-1s
Type 1 Diabetes and GLP-1s SUMMARY There is no known cure for type 1 diabetes GLP-1s do not eliminate the need for insulin and insulin delivery technology in type 1 diabetes • GLP-1s do not eliminate the need for insulin treatment. GLP-1s have not been shown to change the natural course of beta cell
Slide 10: Type 2 Diabetes
Type 2 Diabetes Insulet
Slide 11: Type 2 diabetes is a progressive disease driven by stress on the endocrine system
Type 2 diabetes is a progressive disease driven by stress on the endocrine system and irreversible beta cell decline Over time the body produces less insulin while What causes type 2 diabetes? requiring more1 • Type 2 diabetes is a progressive disease that is diagnosed when Type 2 Pathophysiology in
Slide 12: GLP-1s are one component of the treatment pathway for type 2 diabetes
GLP-1s are one component of the treatment pathway for type 2 diabetes Mechanism of Action of What are the benefits of GLP-1s? GLP-1 Receptor Agonists1 • Improves glucose control and promotes weight loss2 • Reduces the risk of cardiovascular events2 GLP-1 is a hormone that is • Can be used in combina
Slide 13: Available therapies do not stop the underlying progression of type 2 diabetes
Available therapies do not stop the underlying progression of type 2 diabetes Therapies drive initial benefit, Most patients with type 2 diabetes will require however progression persists insulin therapy as disease advances A1C (marker of average blood glucose) progression after second agent introdu
Slide 14: Omnipod is proven and effective in type 2 diabetes
Omnipod is proven and effective in type 2 diabetes Omnipod Classic and DASH improve glycemic control in type 2 diabetes with 32% less insulin usage Reduction in Total Omnipod Classic and Omnipod DASH Reduction in A1C Daily Dose Insulin N=3,592 N=3,053 have been used to treat type 2 -1.3 -33 diabetes
Slide 15: Insulin and GLP-1s are often used in combination, producing better results than either therapy alone
Insulin and GLP-1s are often used in combination, producing better results than either therapy alone Results highlight insulin delivery through Omnipod 51,2 Newer diabetes agents work effectively in is complementary to existing GLP-1 therapy combination with insulin Reduction in A1C with Omnipod 5 n
Slide 16: Large populations progress to insulin therapy, which remain significantly under-penetrated by pumps
Large populations progress to insulin therapy, which remain significantly under-penetrated by pumps Basal Only Basal/Bolus Population Population 2022 2022 ~3M+ 1 ~20 Years of inexorable ~2.5M 193 progression to advanced disease and insulin therapy >99% ~95% 2023 US Adult <1% ~5% Population (M) Insul
Slide 17: Type 2 Diabetes and GLP-1s FAQs
Type 2 Diabetes and GLP-1s FAQS (PART 1 OF 3) How does type 2 diabetes contribute to Insulet’s growth? • The percentage of U.S. new type 2 diabetes customers has ranged from approximately 15% to 40% each quarter since 2019. We also recently disclosed that in Q2 2023, we had a record number of new cu
Slide 18: Type 2 Diabetes and GLP-1s FAQs
Type 2 Diabetes and GLP-1s FAQS (PART 2 OF 3) Do GLP-1s eliminate the need for insulin in type 2 diabetes? Do they drive remission? • GLP-1s do not eliminate the need for insulin in type 2 diabetes. Insulin is recommended in patients whose A1C remains uncontrolled after >3 months of combination ther
Slide 19: Type 2 Diabetes and GLP-1s FAQs
Type 2 Diabetes and GLP-1s FAQS (PART 3 OF 3) Are GLP-1s ever used with insulin? • Yes. Because type 2 diabetes is a progressive disease, maintenance of glycemic targets often requires combination therapy1. There are coformulations available that deliver both GLP-1 and long-acting insulin such as Xu